4.7 Editorial Material

Minimal Residual Disease in Breast Cancer: In Blood Veritas

Journal

CLINICAL CANCER RESEARCH
Volume 20, Issue 10, Pages 2505-2507

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-14-0370

Keywords

-

Categories

Funding

  1. European Community [259015]
  2. AIRC Special Program Molecular Clinical Oncology [9970]
  3. AIRC IG [12812]
  4. Fondazione Piemontese per la Ricerca sul Cancro-ONLUS 5 per mille Ministero della Salute
  5. Ministero dell'Istruzione, dell'Universita e della Ricerca (progetto PRIN)

Ask authors/readers for more resources

blood-based molecular test might direct recommendations for systemic therapies in patients with early-stage breast cancer undergoing surgery with curative intent. A new study suggests that droplet digital PCR (ddPCR) can be used to detect cancer-specific DNA alterations in plasma with sensitivity suitable for monitoring minimal residual disease. (C) 2014 AACR.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available